JP2020523408A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523408A5
JP2020523408A5 JP2020517619A JP2020517619A JP2020523408A5 JP 2020523408 A5 JP2020523408 A5 JP 2020523408A5 JP 2020517619 A JP2020517619 A JP 2020517619A JP 2020517619 A JP2020517619 A JP 2020517619A JP 2020523408 A5 JP2020523408 A5 JP 2020523408A5
Authority
JP
Japan
Prior art keywords
cardiovascular
disease
pharmaceutical composition
canagliflozin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020517619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523408A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/054208 external-priority patent/WO2018229630A1/en
Publication of JP2020523408A publication Critical patent/JP2020523408A/ja
Publication of JP2020523408A5 publication Critical patent/JP2020523408A5/ja
Priority to JP2023077544A priority Critical patent/JP2023113644A/ja
Pending legal-status Critical Current

Links

JP2020517619A 2017-06-12 2018-06-11 ２型糖尿病の患者における心血管イベントの低減又は予防方法 Pending JP2020523408A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077544A JP2023113644A (ja) 2017-06-12 2023-05-10 ２型糖尿病の患者における心血管イベントの低減又は予防方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518547P 2017-06-12 2017-06-12
US62/518,547 2017-06-12
PCT/IB2018/054208 WO2018229630A1 (en) 2017-06-12 2018-06-11 Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077544A Division JP2023113644A (ja) 2017-06-12 2023-05-10 ２型糖尿病の患者における心血管イベントの低減又は予防方法

Publications (2)

Publication Number Publication Date
JP2020523408A JP2020523408A (ja) 2020-08-06
JP2020523408A5 true JP2020523408A5 (https=) 2022-09-27

Family

ID=62916717

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517619A Pending JP2020523408A (ja) 2017-06-12 2018-06-11 ２型糖尿病の患者における心血管イベントの低減又は予防方法
JP2023077544A Withdrawn JP2023113644A (ja) 2017-06-12 2023-05-10 ２型糖尿病の患者における心血管イベントの低減又は予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077544A Withdrawn JP2023113644A (ja) 2017-06-12 2023-05-10 ２型糖尿病の患者における心血管イベントの低減又は予防方法

Country Status (15)

Country Link
US (2) US20180353470A1 (https=)
EP (1) EP3638250A1 (https=)
JP (2) JP2020523408A (https=)
KR (1) KR20200014406A (https=)
CN (1) CN110740735A (https=)
AU (1) AU2018283781B2 (https=)
BR (1) BR112019026120A2 (https=)
CA (1) CA3066874A1 (https=)
CO (1) CO2019013940A2 (https=)
EA (1) EA202090028A1 (https=)
IL (1) IL271100A (https=)
MX (1) MX2019014988A (https=)
TW (1) TWI835735B (https=)
UA (1) UA127987C2 (https=)
WO (1) WO2018229630A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230046951A1 (en) * 2021-08-03 2023-02-16 National Chengchi University System and method for assessing risk of type 2 mellitus diabetes complications
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
NO2385374T3 (https=) * 2010-05-05 2014-06-07
US20130052266A1 (en) * 2010-05-11 2013-02-28 Mitsubishi Tanabe Pharma Corporation TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20160000816A1 (en) * 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2015210898A1 (en) * 2014-01-31 2016-07-28 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders
US20170071970A1 (en) * 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Similar Documents

Publication Publication Date Title
JP7454531B2 (ja) エンパグリフロジンを含む医薬組成物及びその使用
Kimura et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome
JP7020756B2 (ja) 対象の心血管イベントのリスクを低減する方法
Hunt et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation
Vinik et al. Prevention of the complications of diabetes
AU2025202801A9 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
Lundwall et al. Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial
Sakai et al. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction―novel prospective cohort study―
CN110075301A (zh) 依帕列净的治疗用途
TW202108134A (zh) 利用達格列淨治療射血分率降低的心臟衰竭之方法
JP2023113644A (ja) ２型糖尿病の患者における心血管イベントの低減又は予防方法
AU2013241776B2 (en) Basal insulin therapy
JP2020523408A5 (https=)
Maung et al. Hypokalaemic rhabdomyolysis as initial presentation of primary aldosteronism
HK40021204A (en) Method for reducing or preventing cardiovascular events in patients with type ii diabetes mellitus
EP4477224A1 (en) Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high blood uric acid level
Kavanagh Antihypertensive drugs
Al-Harbi An open-label, uncontrolled study to evaluate the effect of verapamil on glycaemic control in type 2 diabetes mellitus patients with hypertension
Faixová et al. THE USE OF SINGLE-PILL COMBINATION THERAPY IN ARTERIAL HYPERTENSION: CASE STUDIES.
Afshinnia et al. Approach to Chronic Kidney Disease in the Diabetic Patient
HK40079514B (en) Methods of reducing the risk of cardiovascular events in a subject
HK40079514A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40038229A (en) Methods of reducing the risk of cardiovascular events in a subject
HK40053699A (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
CA3083432A1 (en) Method of providing celiprolol therapy to a patient